Name: CUVA R1 Recovery Ampoule
Brand: CUVA
SKU: CUVA-R1
Price: 18.00 EUR
Availability: InStock

Full formula

Transparent by design.

Every ingredient in R1 has a specific mechanism. There are no filler actives, no low-dose label plays. Concentrations are calibrated for post-microneedling delivery — where 20–55× normal absorption makes high concentrations not just useful but necessary.

No fragrance. No acids. No retinoids. No parabens. No formaldehyde donors. Open channels mean anything you apply goes in — R1 contains only what you want going in.

pH 4.5–6.0

Format 5ml single-use sterile glass ampoule

Compliance EU 1223/2009

Ingredient	Conc.	Role
GHK-Cu Copper Tripeptide-1	2–5%	Repair, collagen signalling, gene reset, antioxidant
PDRN Polydeoxyribonucleotide	≥1%	Anti-inflammatory + pro-synthesis via A2A receptor
Hyaluronic Acid 20–100 kDa	1–2%	Microchannel delivery vehicle + dermal hydration
Hyaluronic Acid >1 MDa	0.5–1%	Surface calming + film formation
Centella Asiatica	0.5–2%	Asiaticoside anti-inflammatory, soothing
Panthenol (B5)	1–2%	Wound healing, barrier repair
Allantoin	0.2–0.5%	Soothing, stimulates cell proliferation
Phenoxyethanol	≤1%	Preservative — no formaldehyde donors
Aqua	q.s.	Sterile water base

Treatment protocol

Step-by-step application.

Compatible with dermapen, dermaroller, and RF microneedling devices.

01 — Pre-treatment

Cleanse & prep

Cleanse skin thoroughly. Apply topical anaesthetic if required. Confirm no active infection, open wounds, or known allergy to listed ingredients. Do not apply acid toner or alcohol pre-treatment.

02 — Procedure

Standard microneedling

Perform microneedling at recommended depth: 0.3–1.5mm face, 1.5–2.5mm body. R1 is compatible with dermarollers, dermapens, and RF microneedling devices. No protocol changes needed.

03 — Apply R1

Open and apply immediately

Break the sterile ampoule immediately post-treatment. Apply full 5ml to the treated area within 5 minutes. Press gently with clean fingertips — do not rub. Do not rinse for minimum 4 hours.

04 — Post-care

Protect the window

SPF 50+ the following morning. No retinoids, AHAs, BHAs, or Vitamin C for 48 hours. Gentle cleanser only for 24 hours. Optional: apply a hydrogel or sheet mask immediately after R1 to extend occlusion.

05 — Frequency

Session cadence

Recommended: 3 sessions, 4 weeks apart. Maintenance: every 8–12 weeks. One ampoule per patient per session. Do not re-use open ampoules.

06 — Contraindications

Do not use if

Active skin infection or open wounds. Known allergy to any listed ingredient. Pregnancy or breastfeeding (precautionary). Active isotretinoin use (within 6 months). Keloid-prone skin (assess individually).

EU-compliant claims for patient communication

✓ "Supports skin recovery after microneedling" · "Helps soothe and hydrate skin following microneedling procedures"

✓ "With GHK-Cu and PDRN — two of the most-researched cosmetic peptides" · "Formulated for use immediately after microneedling"

Do not claim: "stimulates collagen", "anti-inflammatory", "repairs skin", "delivers into dermis" — these are medicinal claims under EU Regulation EC 1223/2009.

Ingredient science

What each active does.

Mechanism, evidence, and why each ingredient is in R1 at this concentration. All clinical data cited to published peer-reviewed studies.

GHK-Cu

Copper Tripeptide-1

2–5% in R1

Four verified mechanisms

TGF-β receptor signalling for collagen and elastin upregulation. Copper delivery to lysyl oxidase for collagen cross-linking. Antioxidant gene upregulation (SOD1, catalase). Gene expression reset — GHK-Cu modulates 4,000+ human genes toward a younger fibroblast phenotype.

Key data: 134 nmol/mg in skin tissue 9h post-microneedling vs. ~0 on intact skin (Kang Lab, PMID 25690343). Bioactive at 10⁻¹² M (Maquart et al., PMID 3169264). 4,000+ genes modulated (Pickart & Margolina, PMID 29986520).

PDRN

Polydeoxyribonucleotide (salmon-derived)

≥1% in R1

A2A purinergic receptor activation

Activates cAMP → PKA pathway via adenosine A2A receptor — triggering simultaneous anti-inflammatory response (NF-κB suppression, TNF-α/IL-1β/IL-6 down) and pro-synthesis response (TGF-β1, VEGF upregulation). Dual action in the same tissue environment is unique among cosmetic actives.

Key data: PDRN outperformed PRP in microneedling RCT for wrinkle reduction (Vera et al., 2025, p=0.021). ERK phosphorylation + collagen accumulation in dermal fibroblasts (Shin et al., PMID 37350391).

Multi-MW HA

Sodium Hyaluronate (20–100 kDa + >1 MDa)

1.5–3% total in R1

Two-layer delivery system

Short-chain HA (20–100 kDa) penetrates open microchannels into the dermis — acting as a delivery vehicle for the active layer, providing deep hydration, and filling the microchannel space. High-MW HA (>1 MDa) stays at the surface — creates a calming, occlusive film that extends the absorption window.

Why both: Using only one MW leaves either the delivery or the surface protection job undone. R1 uses both fractions at separate functional concentrations.

Centella + Panthenol

Centella Asiatica Extract · Panthenol (B5)

0.5–2% / 1–2% in R1

Recovery support layer

Centella Asiatica (asiaticoside) supports skin comfort in the immediate post-procedure window. Panthenol (provitamin B5) converts to pantothenic acid in skin tissue — supports barrier function and comfort. Allantoin (0.2–0.5%) rounds out the recovery layer: soothing and stimulating cell turnover.

EU claim note: These ingredients allow "soothes and hydrates" and "supports skin recovery after microneedling" claims under EU Regulation EC 1223/2009.

Clinical evidence

Every claim has a source.

Published, peer-reviewed studies on GHK-Cu and PDRN mechanisms and microneedling delivery. CUVA R1 is a cosmetic product. No therapeutic outcomes are implied.

01 — Microneedling delivery

PMID 25690343

Li, Low, Chong et al. — Kang Lab, NUS · Pharmaceutical Research (2015)

Microneedle pretreatment delivered 134 ± 12 nmol GHK-Cu through human skin in 9 hours. Near-zero penetration through intact skin under identical conditions.

PMC3160154

Kalluri, Kolli & Banga · AAPS Journal (2011)

Skin barrier recovers 4–5 hours post-poration; full pore closure at 12–18 hours depending on depth. Occlusive dressing delays closure further.

PMC4590292

Zhang, Qiu & Gao · Acta Pharmaceutica Sinica B (2014)

Microneedle arrays significantly enhanced transdermal flux of hydrophilic peptides (456–1007 Da). 20–55× delivery increase vs. intact skin.

PMC4102460

Mohammed, Yamada, Lin et al. · PLoS One (2014)

2–22-fold signal improvement for cosmeceutical peptide delivery into ex vivo human skin via microneedles vs. passive topical application.

02 — GHK-Cu (Copper Tripeptide-1)

PMID 3169264

Maquart, Pickart, Laurent et al. · FEBS Letters (1988)

GHK-Cu stimulates collagen synthesis in human fibroblast cultures at 10⁻¹² M. Activity independent of cell proliferation. Foundational sub-nanomolar bioactivity data.

PMID 29986520

Pickart & Margolina · Int J Mol Sci (2018)

GHK modulates expression of 4,000+ human genes — upregulating tissue repair and antioxidant pathways while downregulating inflammatory and degenerative gene sets.

PMID 20703511

Hostynek, Dreher & Maibach · Inflammation Research (2010)

136.2 µg/cm² copper permeated dermatomed human skin passively over 48h; 82 µg/cm² retained as dermal depot. Clinically relevant passive penetration confirmed.

PMID 39963574

Mortazavi et al. · BioImpacts (2025)

2025 review confirms GHK anti-wrinkle properties. Skin penetration identified as primary challenge — complexation and microneedle delivery validated as solutions.

03 — PDRN (Polydeoxyribonucleotide)

PMID 28491036

Squadrito, Bitto, Irrera et al. · Frontiers in Pharmacology (2017)

PDRN's primary mechanism: A2A receptor engagement activating tissue repair, anti-ischemic, and anti-inflammatory cascades through the nucleoside salvage pathway.

PMID 37350391

Shin, Baek, Kim et al. · Molecular Medicine Reports (2023)

PDRN increases ERK phosphorylation and collagen accumulation in dermal fibroblasts while suppressing TNF-α, IL-1β, and IL-6 — dual pro-repair and anti-inflammatory action.

DOI 10.57662/am.v11i2.16753

Vera, Praharsini, Darwinata et al. · Aesthetic Medicine (2025)

RCT (n=24): microneedling + PDRN 3% achieved significantly greater Lemperle wrinkle score reduction than microneedling + PRP (p=0.021).

All references cite published peer-reviewed studies on ingredient mechanisms and delivery conditions under specific experimental or clinical parameters. Results are not a guarantee of product outcomes. CUVA R1 is a cosmetic product regulated under EU Regulation EC 1223/2009. No therapeutic or medical claims are made or implied.

R1